Leukemia Therapy – A Look Into the Future
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
Disadvantaged Neighborhoods, Modifiable Chronic Health Conditions Are Associated With Late Deaths in Survivors of Childhood Cancer
Living in a socioeconomically disadvantaged neighborhood or living with modifiable chronic health conditions were associated with an increased risk for death 5 years of more following diagnosis among survivors of childhood cancer, according to findings from a cohort study.
CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through AccountabilityMarch 22nd 2023
Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.
MEDI9253 Plus Durvalumab Delivers Little Efficacy in Advanced/Metastatic Solid TumorsMarch 22nd 2023
The addition of MEDI9253 to sequential or concurrent treatment with durvalumab failed to elicit more than 1 partial response although proving feasible and safe in patients with advanced or metastatic solid tumors, according to findings from a phase 1 trial.
FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection
A new drug application seeking the approval of Lumisight, an optical imaging agent that detects cancerous tissue during initial lumpectomy to allow for a more complete resection, has been submitted to the FDA.
Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCLMarch 21st 2023
Axicabtagene ciloleucel produced a statistically significant improvement in overall survival compared with standard-of-caretherapy in patients with relapsed/refractory large B-cell lymphoma, according to data from the ZUMA-7 trial.
FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple MyelomaMarch 21st 2023
The FDA has granted an orphan drug designation to ISB 1442, the first-in-class biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 for the treatment of patients with relapsed/refractory multiple myeloma.
HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain
Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.
Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FLMarch 21st 2023
A real-world analysis exploring the outcomes of inpatient vs outpatient administration of CAR T-cell therapy in patients with mantle cell lymphoma and follicular lymphoma demonstrated both similarities and some differences between the 2 patient populations.
Allocetra Plus Chemotherapy Receives Green Light to Continue Investigation in Solid Tumors With Peritoneal MetastasisMarch 20th 2023
The phase 1/2 trial evaluating the addition of Allocetra to standard chemotherapy administered via pressurized intraperitoneal aerosol chemotherapy received regulatory clearance to continue evaluation and launch the dose-escalation cohort in patients with advanced-stage peritoneal metastasis arising from solid tumors following the completion of an interim data review by an Independent Data and Safety Monitoring Board and the Israeli Ministry of Health.
Dostarlimab Fills Unmet Need for Patients with dMMR Advanced Endometrial CancerMarch 20th 2023
Lucy Gilbert, MD, MSc, discusses the favorable safety profile of dostarlimab as well as how it compares with the current standard of care in mismatch repair deficient advanced endometrial cancer.
FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast CancerMarch 20th 2023
Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.
Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast CancerMarch 20th 2023
Patritumab deruxtecan elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer and patients with HER3-expressing metastatic breast cancer.
First-line ASCT Consolidation Confers Real-world Survival Benefit in Mantle Cell LymphomaMarch 20th 2023
Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.
Integrating New Standards for Metastatic HER2+ Breast CancerMarch 20th 2023
The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.
Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung CancerMarch 20th 2023
Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.
ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell LymphomaMarch 19th 2023
First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.
Triplets and Targeted Therapies May Strengthen the R/R AML ArmamentariumMarch 18th 2023
Eunice Wang, MD, discusses the current standards for classifying and treating unfit patients with AML, treatment considerations for patients unfit for hypomethylating agents, and the potential role of investigational menin inhibitors and immunotherapies in this population.
Maintenance Avelumab Plus Lurbinectedin Under Investigation in Metastatic Urothelial CarcinomaMarch 17th 2023
Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.